Genome-wide association study of cognitive function in diverse Hispanics/Latinos: results from the Hispanic Community Health Study/Study of Latinos.

https://escholarship.org/uc/item/1x8741h2

Translational psychiatry, 10(1)

2158-3188

Jian, Xueqiu
Sofer, Tamar
Tarraf, Wassim
et al.

2020-07-22

10.1038/s41398-020-00930-2

Peer reviewed
Genome-wide association study of cognitive function in diverse Hispanics/Latinos: results from the Hispanic Community Health Study/Study of Latinos

Xueqiu Jian1,2, Tamar Sofer3, Wassim Tarraf4, Jan Bressler5, Jessica D. Faul6, Wei Zhao7, Scott M. Ratliff7, Melissa Lamar8, Lenore J. Launer9, Cathy C. Laurie10, Neil Schneiderman11, David R. Weir6, Clinton B. Wright12, Kristine Yaffe13, Donglin Zeng14, Charles DeCarli15, Thomas H. Mosley16, Jennifer A. Smith6,7, Hector M. González17 and Myriam Fornage1,5

Abstract
Cognitive function such as reasoning, attention, memory, and language is strongly correlated with brain aging. Compared to non-Hispanic whites, Hispanics/Latinos have a higher risk of cognitive impairment and dementia. The genetic determinants of cognitive function have not been widely explored in this diverse and admixed population. We conducted a genome-wide association analysis of cognitive function in up to 7600 middle aged and older Hispanics/Latinos (mean = 55 years) from the Hispanic Community Health Study / Study of Latinos (HCHS/SOL). Four cognitive measures were examined: the Brief Spanish English Verbal Learning Test (B-SEVLT), the Word Fluency Test (WFT), the Digit Symbol Substitution Test (DSST), the Six-Item Screener (SIS). Four novel loci were identified: one for B-SEVLT at 4p14, two for WFT at 3p14.1 and 6p21.32, and one for DSST at 10p13. These loci implicate genes highly expressed in brain and previously connected to neurological diseases (UBE2K, FRMD4B, the HLA gene complex). By applying tissue-specific gene expression prediction models to our genotype data, additional genes highly expressed in brain showed suggestive associations with cognitive measures possibly indicating novel biological mechanisms, including IFT122 in the hippocampus for SIS, SNX31 in the basal ganglia for B-SEVLT, RPS6KB2 in the frontal cortex for WFT, and CSPG5 in the hypothalamus for DSST. These findings provide new information about the genetic determinants of cognitive function in this unique population. In addition, we derived a measure of general cognitive function based on these cognitive tests and generated genome-wide association summary results, providing a resource to the research community for comparison, replication, and meta-analysis in future genetic studies in Hispanics/Latinos.

Introduction
Cognitive function refers to a set of cerebral activities such as reasoning, attention, memory, and language, which are supported by specific neuronal networks in the brain. These functions are highly correlated with brain aging. Various cognitive tests were developed to assess different aspects of these functions quickly and non-invasively, and have proven to be valid measures of brain function and the onset of dementia1-4. Twin studies suggested that inter-individual variation in cognitive function has a genetic component5-8. Several genome-wide association studies (GWAS) have been conducted...
and identified common variants associated with various measures of cognitive function\textsuperscript{9–13}, which aside from the apolipoprotein E (APOE) region have yielded a limited number of replicable loci. However, these have been conducted primarily in populations of European ancestry\textsuperscript{14}. The Hispanic/Latino population is the largest ethnic/racial minority group in the United States (US), with an estimate of 58.9 million, representing 18.1% of the total US population in 2017\textsuperscript{15}. The risk of cognitive impairment and dementia is higher in US ethnic/racial minorities such as Hispanics/Latinos than in non-Hispanic whites\textsuperscript{16}. US Hispanic/Latino populations are diverse in many respects, including history, culture, and socioeconomic factors. They also vary in cognitive function, which cannot be fully explained by these factors\textsuperscript{17}. Genetically, the US Hispanic/Latino population is uniquely admixed, representing Amerindian, African, and European continental ancestries\textsuperscript{18}. Results from GWAS in populations of European ancestry may or not be generalizable to Hispanic/Latino populations. While some GWAS studies of late-onset Alzheimer’s disease (LOAD) have been carried out in Caribbean Hispanics (Dominican and Puerto Rican)\textsuperscript{19,20}, to our knowledge, no GWAS of cognitive function has, to date, been reported in a diverse Hispanic/Latino population that includes Cubans, Dominicans, Puerto Ricans, Mexicans, Central Americans, and South Americans.

In this study, we sought to examine genetic associations with cognitive function among diverse middle-aged and older Hispanics/Latinos within the Hispanic Community Health Study/Study of Latinos (HCHS/SOL).

Materials and methods

Study sample

The subjects were drawn from the HCHS/SOL, a community-based cohort study with the goal of identifying risk or protective factors for cardiovascular and pulmonary diseases among diverse US Hispanics/Latinos. A total of 16 415 self-identified Hispanic/Latino adults, 18 to 74 years old, were recruited from four US metropolitan areas (Bronx, New York; Chicago, Illinois; Miami, Florida; and San Diego, California) between 2008 and 2011. Various biospecimen and health information about risk/protective factors were collected at the Visit 1 examination\textsuperscript{21,22}. The HCHS/SOL study was approved by institutional review boards at participating institutions, including each field center, coordinating center, and the University of Texas Health Science Center at Houston. Written informed consent was obtained from all participants.

Measures of cognitive function

A subset of the HCHS/SOL sample with middle-aged and older participants (age ≥ 45 years, sample size = 9652) underwent cognitive assessment including the Six-Item Screener (SIS, global mental status), Brief Spanish English Verbal Learning Test (B-SEVLT, verbal learning and memory), Word Fluency Test (WFT, executive and verbal functioning), and Digit Symbol Substitution Test (DSST, psychomotor speed and sustained attention)\textsuperscript{17}. We did not exclude patients with dementia or mild cognitive impairment because they were not ascertained at this visit. Each test has been previously described\textsuperscript{17} and is summarized in Supplementary Table 1. Because the distribution of the SIS score is skewed in our sample, we dichotomized this measure, with a score of 0 to 4 indicating low mental status and 5 or 6 indicating normal mental status\textsuperscript{17}. We also derived a measure of general cognitive function (G) for each study participants as described by Davies et al.\textsuperscript{14}. Specifically, G is defined as the value on the first unrotated principal component (PC1) of the standardized scores for B-SEVLT, WFT, and DSST.

Genotyping, imputation and quality control

Details of genotyping and imputation were reported elsewhere\textsuperscript{23}. In brief, 12,803 participants were successfully genotyped at ~2.4 million variants including single nucleotide variants (SNVs) and insertions/deletions (indels) on an Illumina custom array and passed the standard quality-assurance and quality-control procedures\textsuperscript{24}. These genotypes were then pre-phased, followed by imputation with the 1000 Genomes Phase III reference panel, yielding over 50 million imputed variants. For association testing additional quality control was applied based on effective minor allele count (effN), which was defined as $2 \times \text{MAF} \times (1 - \text{MAF}) \times \text{sample size} \times \text{imputation quality}$, where MAF is the minor allele frequency of a variant in the sample. A single variant was assessed for association if effN ≥ 30 for quantitative measure (B-SEVLT, WFT, DSST, and G) or effN ≥ 50 in both categories for binary measure (dichotomized SIS).

Genome-wide association analyses

We performed genetic association analyses with measures of cognitive function using a linear mixed model (LMM). For dichotomized SIS, we used the penalized quasi-likelihood method to approximate the more computationally intensive generalized LMM\textsuperscript{25}. In the mixed model for each measure, we included sex, baseline age, recruitment center, sampling weight that corrects for potential bias introduced by the sampling procedure, and the top five principal components that account for population stratification due to ancestry variation, as fixed effects. In addition, we included the “genetic-analysis group”, a categorical variable (Central American, Cuban, Dominican, Mexican, Puerto Rican, and South American) constructed based on self-identified background group
and genetic variation (thus more genetically homogeneous within groups), as a fixed effect. For quantitative cognitive measures, we further specified the model to allow for heterogeneous residual variances among ancestry groups defined by the "genetic-analysis group"\textsuperscript{18}. Meanwhile, we fitted the mixed model with random effects due to kinship, household, and block group. All analyses were performed with the GENetic ESTimation and Inference in Structured samples (GENESIS) Bioconductor package\textsuperscript{26}. For each cognitive measure, the threshold of \( p < 5 \times 10^{-8} \) was used to identify genome-wide significant variants.

Because cognitive function and education are correlated both genetically and phenotypically, our primary analyses did not adjust for education so as to maximize our power to identify genetic variants. However, in secondary analyses, education level (<high school, = high school, or >high school) was included as a covariate to assess whether our genetic findings are confounded by education. Genome-wide association analyses were conducted in a total sample of 7606 individuals with available genotype and phenotype data.

**Ancestry-specific allele frequency estimate for top variants and their replication in independent samples**

To help select the appropriate population for replication of our top GWAS variants, we first estimated their ancestry-specific allele frequencies using the ASAFE algorithm\textsuperscript{27}. Our replication sample included three studies: the Atherosclerosis Risk in Communities (ARIC) study\textsuperscript{28}, the Coronary Artery Risk Development in Young Adults (CARDIA) study\textsuperscript{29}, and the Health and Retirement Study (HRS)\textsuperscript{30}. All three studies contain individuals of European and African ancestries. A proportion of the HRS participants are Hispanic. A detailed description of the replication samples is provided in Supplementary Methods. Measures of cognitive function in each of the replication studies as well as the demographic information are summarized in Supplementary Table 2. Linear (or logistic) regression models were used to test the association of selected variants with measures of cognitive function in the replication samples. Results from each replication sample were then combined by fixed effect meta-analysis.

**Lookup of previously identified GWAS signals and meta-analysis of general cognitive function**

In our data, we looked up genome-wide significant variants reported in the recently published largest GWAS of general cognitive function in the population of European ancestry by Davies et al. \( N > 300,000 \)\textsuperscript{14}. using a Bonferroni-corrected threshold for 148 independent loci identified. Reciprocally, we also examined whether any of our genome-wide significant loci showed evidence of association by Davies et al.\textsuperscript{14}. Because our identified variants may, themselves, not be causal but rather may tag (a) potential causal variant(s) and because of differences in linkage disequilibrium (LD) among the populations in the two studies, we performed a look-up on all proxies in LD with our top variants in Europeans \( \left( r^2 \geq 0.6 \right) \) and we examined all variants within 100 kb of our top variant at each locus.

To identify additional loci for general cognitive function, we meta-analyzed the GWAS results for general cognitive function in the two studies, restricting to over 20,000 variants that showed suggestive association \( \left( 10^{-5} < p < 5 \times 10^{-8} \right) \) in the Davies et al GWAS, using a z-based N-weighted approach.

**Phenotype correlation, heritability and genetic correlation estimate**

The correlation between each pair of cognitive measures in our study was estimated using Pearson correlation. We then applied the GREML approach implemented in the GCTA\textsuperscript{31} to estimate variance explained by common variants for each measure of cognitive function, using the kinship coefficients estimated by Conomos et al.\textsuperscript{18}. We also used the bivariate GREML method to estimate the genetic correlation between each pair of the cognitive function measures\textsuperscript{32}. Compared to LD-based methods, the GREML provides more accurate estimates while requiring smaller sample sizes.

**Fine-mapping GWAS loci using epigenomic annotations**

To further prioritize risk variants within a locus, we integrated epigenomic annotations with GWAS summary statistics using a Bayesian framework RIVIERA\textsuperscript{33}. We first obtained narrow peaks for the histone ChIP-seq and DNase-seq for 848 epigenome tracks in 127 cell/tissue types including 8 epigenomic marks (H3K4me1, H3K4me3, H3K36me3, H3K27me3, H3K9me3, H3K27ac, H3K9ac and DNase I) from the ENCODE/Roadmap and then overlapped variants at each locus with a narrow peak of an annotation. Bayesian inference was performed to estimate the posterior probability of association (PPA) for each variant within the locus taking into account its epigenomic context.

**Functional mapping and annotation of top GWAS loci**

We implemented FUMA v1.3.0 to functionally annotate and prioritize our GWAS results\textsuperscript{34}. Specifically, information from 18 biological data repositories and tools was used to annotate variants with GWAS \( p < 5 \times 10^{-8} \) and variants in LD with them \( \left( r^2 \geq 0.6 \right) \) for each measure of cognitive function. Next, candidate genes were identified using positional mapping, eQTL mapping, and chromatin interaction mapping.
Tissue-specific prediction of gene expression associated with cognitive function

We applied PrediXcan\(^\text{35}\) to predict and test for association of genetically regulated gene expression in brain tissues with each individual measure of cognitive function. We first estimated genetically regulated gene expression level in 10 brain tissues from each individual’s genotype using tissue-specific, whole-genome prediction model trained with reference transcriptome from the GTEx database. We then tested association between predicted tissue-specific gene expression with individual measures of cognitive function using the same LMM as was applied in the GWAS. Statistical significance was established using a Bonferroni correction.

Gene-based and pathway analysis

Gene-based analysis using GWAS summary statistics was performed using fastBAT\(^\text{36}\) implemented in the GCTA. Pathway analysis was performed using DEPICT\(^\text{37}\) to prioritize genes, pathways and tissue/cell types.

Shared genetic contribution to cognitive function and related cognitive traits

Using results from published GWAS, we generated polygenic risk scores (PRS) of cognitive function and related cognitive traits in the HCHS/SOL participants and estimated the shared genetic contribution among these traits using PRSice\(^\text{38}\). Summary statistics were obtained from GWAS of educational attainment\(^\text{39}\), general cognitive function\(^\text{14}\), reaction time\(^\text{14}\), major depression disorder\(^\text{40}\), neuroticism\(^\text{41}\), schizophrenia\(^\text{42}\), LOAD\(^\text{43}\), and MRI-defined white matter hyperintensities\(^\text{44}\) and hippocampal volume\(^\text{45}\). For each trait, the most predictive PRS was identified and regressed against each of the cognitive tests in our study, adjusting for fixed and random effects.

Results

Table 1 shows the summary statistics of the sample in our analysis including sample size, distribution of phenotype, age, sex, and education level for each measure of cognitive function.

We tested ~ 20 million SNVs and indels in up to 7600 US Hispanics for association with each measure of cognitive function. Potential population stratification of this diverse sample was well controlled (Supplementary Fig. 1). We identified one locus at 4p14 for B-SEVLT (lead SNV: rs113719683, \(p = 3.7 \times 10^{-3}\)) with three common SNVs (MAF = 6%) in high LD with each other (\(r^2 \geq 0.98\)); one common indel (rs59912956: MAF = 19%, \(p = 5.09 \times 10^{-10}\)) at 3p14.1 and one rare indel (rs568391433: MAF = 0.4%, \(p = 1.07 \times 10^{-8}\)) at 6p21.32 (HLA locus) for WFT; and one locus at 10p13 for DSST (lead SNV: rs74610382, \(p = 5.04 \times 10^{-9}\)) with six rare SNVs (MAF = 0.3%) in high LD with each other (\(r^2 \geq 0.78\)) (Fig. 1; Table 2).

Adjustment for education level did not diminish the significance of the variants associated with B-SEVLT and WFT meaningfully, but had an impact on those associated with DSST, though they remained nominally significant (Table 2). Ancestry-specific allele frequency estimates showed that the three SNVs associated with B-SEVLT on chromosome 4 are observed most commonly in European ancestry; the rare indel associated with WFT is only observed in European ancestry. The common indel associated with WFT is observed in all 3 continental populations at similar frequency, while the six rare SNVs on chromosome 10 associated with DSST are observed only in African ancestry (Table 2). We tested these variants for replication in independent samples of ancestry corresponding to the most likely continental origin of the associated allele according to our estimated ancestry-specific allele frequencies, using the same or similar test that measure the same functional domain (Supplementary Table 2). The meta-analysis p-values in replication samples are shown in Table 2. Though none of these variants were replicated, the associations of the effect allele have the same direction comparing to those in the discovery sample (binomial test indicating such observation is not random \(p < 0.001\)).

We also performed a look-up of our identified loci in the largest GWAS of general cognitive function (G) reported to date in a population of mostly European ancestry\(^\text{14}\). None of our genome-wide significant variants or their proxies were present in that GWAS, probably due to the filtering strategy used. However, because our identified SNPs may, themselves, not be causal but rather may tag (a) potential causal SNP(s) and because patterns of LD differ between Hispanics/Latinos and populations of European ancestry, direct look-up of our identified SNPs may not be informative or appropriate. Hence, we examined whether any SNPs located within 100 kb around our top SNPs showed evidence of association with G in Davies et al. \((p < 0.05/4 \text{ loci} = 1.25 \times 10^{-2})\). For all 4 loci, we observed some evidence of association with general cognitive function (Supplementary Table 3). The strongest evidence was for the locus at 6p21.32 (108 SNPs; lowest \(p = 1.9 \times 10^{-4}\), rs3129267).

Reciprocally, we looked up all 11 600 genome-wide significant variants reported in the largest GWAS of general cognitive function to date\(^\text{4}\) among which 8 variants from 2 loci reached the Bonferroni-corrected significance threshold \((p < 3.4 \times 10^{-4}\) (Supplementary Table 4).

To facilitate comparison of findings in this diverse population of Hispanics/Latinos with those reported in the largest GWAS of cognitive function to date\(^\text{14}\), we also performed a GWAS of general cognitive function (PC1) defined as in Davies et al\(^\text{14}\). No variant reached genome-
Table 1 Characteristics of participants for each individual measure of cognitive function.

|                      | Total          | Central American | Cuban          | Dominican       | Mexican         | Puerto Rican    | South American  |
|----------------------|----------------|------------------|----------------|----------------|----------------|----------------|-----------------|
| N (％female)         | 7606 (61%)     | 762 (65%)        | 1506 (53%)     | 709 (65%)      | 2608 (63%)     | 1462 (60%)     | 559 (62%)       |
| Mean age (SD)        | 55 (6)         | 55 (7)           | 56 (8)         | 55 (8)         | 55 (6)         | 56 (8)         | 55 (7)          |
| % Education ≥ high school | 58%          | 57%              | 72%            | 50%            | 48%            | 56%            | 75%             |
| Mean score (SD)      |                |                  |                |                |                |                |                 |
| SIS (dichotomized)   | 85%            | 88%              | 87%            | 77%            | 88%            | 78%            | 89%             |
| B-SEVLT              | 8 (3)          | 9 (3)            | 8 (3)          | 8 (3)          | 9 (3)          | 7 (3)          | 9 (3)           |
| WFT                  | 18 (7)         | 18 (7)           | 18 (7)         | 16 (7)         | 19 (8)         | 17 (7)         | 21 (7)          |
| DSST                 | 34 (13)        | 30 (12)          | 34 (12)        | 27 (12)        | 35 (14)        | 36 (14)        | 36 (13)         |

*Proportion of participants with score of 5 or 6. N sample size, SD standard deviation, SIS six-item screener, B-SEVLT brief Spanish English verbal learning test, WFT word fluency test, DSST digit symbol substitution test.

Fig. 1 Manhattan plots of the genome-wide association study results for each cognitive test. a Brief Spanish English Verbal Learning Test (B-SEVLT); b Word Fluency Test (WFT); and c Digit Symbol Substitution Test (DSST). The red horizontal line represents the genome-wide significance threshold ($p < 5 \times 10^{-8}$) and the green dot represents the significant variants in each analysis.
Table 2  Genome-wide significant variants for each measure of cognitive function, their ancestry-specific allele frequency estimate, and replication in independent samples.

| Test      | Variant   | chr | Position  | Coded allele | Other allele | Coded allele frequency | N   | Beta (se)    | P-value | P-value (edu-adj) | Ancestry-specific allele frequency<sup>a</sup> | Replication P-value<sup>b</sup> |
|-----------|-----------|-----|-----------|--------------|--------------|------------------------|-----|--------------|---------|-------------------|---------------------------------------------|-------------------------------|
|           |           | 4   | 40433446  | T            | C            | 0.939                  | 7562| 0.6 (0.1)   | 3.70E-08 | 6.70E-08          | 0.997                        | 0.926                        | 1.000 | 0.800                  |
| B-SEVLT   | rs113719683 | 4   | 40433442  | A            | G            | 0.939                  | 7562| 0.6 (0.1)   | 4.06E-08 | 6.81E-08          | 0.997                        | 0.927                        | 1.000 | 0.709                  |
|           | rs112927755 | 4   | 40433460  | G            | A            | 0.940                  | 7562| 0.6 (0.1)   | 4.32E-08 | 7.13E-08          | 0.997                        | 0.927                        | 1.000 | 0.775                  |
| WFT       | rs59912956 | 3   | 69592250  | GA           | GAA          | 0.814                  | 7446| 1.0 (0.2)   | 5.09E-10 | 2.46E-09          | 0.815                        | 0.828                        | 0.805 | 0.434<sup>c</sup>     |
|           | rs568391433 | 6   | 33004530  | C            | CT           | 0.996                  | 7446| −5.8 (1.0) | 1.07E-08 | 5.09E-08          | 1.000                        | 0.995                        | 1.000 | 0.356<sup>c</sup>     |
| DSST      | rs74610382 | 10  | 16254360  | G            | A            | 0.997                  | 7372| 10.8 (1.8) | 5.04E-09 | 1.32E-06          | 1.000                        | 1.000                        | 0.985 | 0.330                  |
|           | rs116623781 | 10  | 16226698  | G            | A            | 0.997                  | 7372| 10.3 (1.8) | 5.05E-09 | 2.05E-06          | 1.000                        | 1.000                        | 0.984 | 0.310                  |
|           | rs181182078 | 10  | 16260622  | A            | T            | 0.997                  | 7372| 10.7 (1.8) | 5.94E-09 | 1.88E-06          | 1.000                        | 1.000                        | 0.985 | 0.658                  |
|           | rs150206471 | 10  | 16220142  | C            | T            | 0.997                  | 7372| 10.4 (1.8) | 7.44E-09 | 6.27E-07          | 1.000                        | 1.000                        | 0.984 | 0.327                  |
|           | rs142289140 | 10  | 16264277  | C            | G            | 0.997                  | 7372| 10.5 (1.8) | 8.31E-09 | 2.91E-06          | 1.000                        | 1.000                        | 0.985 | 0.786                  |
|           | rs115696258 | 10  | 16270189  | C            | T            | 0.997                  | 7372| 10.5 (1.8) | 1.11E-08 | 3.47E-06          | 1.000                        | 1.000                        | 0.986 | 0.379                  |

<sup>a</sup>Ethnic groups used in replication were determined by estimated ancestry-specific allele frequency (in bold).

<sup>b</sup>Replication P-values were generated by meta-analysis of ARIC, CARDIA and HRS. The direction of association with the effect allele for all variants are the same in the discovery and replication samples.

<sup>c</sup>The two variants for WFT were only observed in HRS so that the meta-analysis P-values were contributed solely by HRS. B-SEVLT brief Spanish English verbal learning test, WFT word fluency test, DSST digit symbol substitution test, chr chromosome, N sample size, SE standard error, edu-adj education adjusted, ARIC atherosclerosis risk in communities, CARDIA coronary artery risk development in young adults, HRS health and retirement study.
wide significance although 14 variants in 6 loci reached the suggestive threshold of \( p < 5 \times 10^{-7} \) (Supplementary Table 5). Seven of the 14 variants (4 loci) were directly observed in Davies et al. but did not show evidence of association with general cognitive function in our study. All but one locus harbored multiple SNPs within 100 kb of the top SNP, which showed evidence of association with G, with the strongest evidence for a locus at 12p12.3 (35 SNPs; lowest \( p = 3.5 \times 10^{-6}, \) rs7965359). Notably, the locus at 3p14.1 associated with WFT showed also evidence of association with G (rs59912956, \( p = 7.3 \times 10^{-8} \)).

Finally, we performed a meta-analysis of our general cognitive function GWAS with results from Davies et al.\(^{14}\), which yielded 625 additional genome-wide significant variants (Supplementary Fig. 2). Among these, 160 were independent (\( r^2 < 0.6 \)) from the previously reported variants in Davies et al.\(^{14}\) and represented 30 loci. Twenty-six of these loci (89 variants) showed low to moderate heterogeneity in the meta-analysis (\( I^2 < 50\% \)) (Supplementary Table 6).

We estimated the proportion of phenotypic variance explained by common variants for each measure of cognitive function as well as the pairwise phenotypic and genetic correlations among the cognitive measures (Table 3). Individual measures of cognitive function show weak to moderate phenotypic correlation to each other (\( r = 0.19 \sim 0.47 \)), whereas G was highly correlated with its component scores (\( r \geq 0.7 \)). Common variants explained a small proportion of the phenotypic variance for all measures of cognitive function (\( h^2 = 0.08 \sim 0.31 \)). Genetic correlations between B-SEVLT and WFT/DSST were not significant (\( r = 0.31 \) and 0.18, respectively). The remaining pairwise correlations were significant and showed a moderate to strong genetic correlation (\( r = 0.54 \sim 0.85 \)).

Functional annotation of the variants reaching genome-wide significance for cognitive measures in the present study is shown in Supplementary Table 7. All of the associated variants mapped to non-coding regions of the genome. To link the associated variants to genes, we applied the 3 gene-mapping strategies implemented in FUMA and summarized in Fig. 2. While these analyses are helpful to point to candidate genes with potential functional impact on cognitive function, higher credibility is given to those with convergent evidence from multiple analyses. For example, the SNVs at 4p14 associated with B-SEVLT mapped to intronic regions of the \textit{RBM47} gene and were identified as eQTLs for 4 genes: \textit{RBM47}, \textit{APBB2}, \textit{N4BP2} and \textit{UBE2K}. In our PrediXcan analyses, the genetically-predicted gene expression of \textit{UBE2K} in the basal ganglia was nominally associated with B-SEVLT (\( p = 0.036 \)). Similarly, the variant at 6p21.32 associated with WFT mapped to the \textit{HLA} region. Among the genes implicated by chromatin interaction mapping (Fig. 2), genetically-predicted gene expression of \textit{HLA-DMB} in the frontal cortex was associated with WFT in our PrediXcan analyses (\( p = 0.019 \)). The variant at 3p14.1 associated with WFT mapped upstream of \textit{FRMD4B} and was in moderate LD (\( r^2 = 0.6 \)) with variants annotated as eQTLs of \textit{FRMD4B} and the pseudogene \textit{RBM43P1}. The SNVs at

### Table 3  Heritability, genetic and phenotypic correlation estimate.

|          | SIS  | B-SEVLT | WFT  | DSST | G    |
|----------|------|---------|------|------|------|
| SIS      | 0.075 | 0.629   | 0.544 | 0.686 | 0.818 |
| B-SEVLT  | 0.245 | 0.126   | 0.310* | 0.183* | 0.566 |
| WFT      | 0.190 | 0.322   | 0.194 | 0.564 | 0.849 |
| DSST     | 0.252 | 0.363   | 0.471 | 0.306 | 0.841 |
| G        | 0.285 | 0.698   | 0.786 | 0.813 | 0.223 |

\(SIS: \) Six-Item Screener; \(B-SEVLT: \) Brief Spanish English Verbal Learning Test; \(WFT: \) Word Fluency Test; \(DSST: \) Digit Symbol Substitution Test; \(G: \) General cognitive function (PC1).
10p13 associated with DSST mapped to an intergenic region. Chromatin interaction mapping implicated a gene encoding a lincRNA, *RP11-461K13.1*. Using RiVIERA, we inferred that among the six genome-wide significant rare variants at 10p13 for DSST, rs142289140 is more likely to be causal (PPA = 0.75), taking into account the epigenomic context at this locus (Supplementary Fig. 3).

In addition to selected genes implicated by our GWAS analyses, our PrediXcan analysis in multiple brain tissues showed no genes significantly associated with any of the cognitive measures after correcting for multiple comparisons, but we identified several suggestive associations. Notable findings include *IFT122* in the hippocampus for SIS (*p* = 8.13 × 10^{-5}), *SNX31* in the basal ganglia for B-SEVL (p = 3.74 × 10^{-5}), *RPS6KB2* in the frontal cortex for WFT (p = 3.91 × 10^{-5}), and *CSPG5* in the hypothalamus for DSST (p = 6.80 × 10^{-5}) (Supplementary Fig. 4). No single variant within these genes, however, showed an association with the corresponding cognitive test (Supplementary Fig. 5).
The gene-based and pathway analyses did not yield significant results for any measure of cognitive function (Supplementary Table 8). Gene-set enrichment analysis using FUMA-implicated genes in all 4 GWAS loci showed a significant enrichment for genes previously reported in GWAS of autism spectrum disorder and schizophrenia (Supplementary Fig. 6).

PRS for educational attainment and general cognitive function were associated with all cognitive traits but explained little of the phenotypic variance in our sample. For example, the PRS for general cognitive function explained only a little more than 1% of the variance of G (Supplementary Table 9). These results must be interpreted cautiously in light of the known complexity of PRS transferability and performance in non-European populations [46,47].

**Discussion**

We conducted a GWAS of multiple measures of cognitive function in a large and diverse sample of middle-aged and older US Hispanics/Latinos. We identified four novel loci encompassing genes previously implicated in neurological and psychiatric disorders. However, we were unable to convincingly establish an association of these loci with cognitive function in independent samples. In addition, few loci identified in populations of European ancestry demonstrated evidence of an association with cognitive function in this diverse sample of Hispanics/Latinos. Our study underscores the need for expanding genetic studies in this under-studied population and illustrates the challenges of replicating and interpreting findings in light of the paucity of genetic data from large and diverse Hispanic/Latino samples. Indeed, while GWAS have become the standard tool for exploring the genetic basis of human complex traits, as of 2019, Hispanic/Latino populations represent only 1% of individuals in these studies [48,49]. This is despite the recognition that increasing human subject diversity improves genetic discoveries [50]. Over 18% of the total US population are Hispanics/Latinos and their under-representation in genetic studies is likely to further exacerbate existing health disparities by limiting clinical applications of genetic research, such as risk prediction [48,49].

Acknowledging the complexity of PRS transferability and performance in non-European populations [46,47], our finding that polygenic risk scores for general cognitive function or educational attainment estimated based on European ancestry data explain little of the variance in measures of cognitive function in diverse Hispanics/Latinos nonetheless further illustrates this argument.

Our study has considerable strengths. Considering the complexity of Hispanic/Latino ancestries, the multi-stage and multi-center sampling design of the HCHS/SOL made it the most diverse representative sample of the US Hispanic/Latino population to date. We used LMM and adjustment for "genetic-analysis group" to account for relatedness and genetic heterogeneity among ethnic groups. In this GWAS, we identified common and low frequency SNVs and indels associated with the performance in three cognitive tests that measure different functional domains in the brain. Inference of causal variants identified in this GWAS is challenging because GWAS signals are LD-based and mostly map within non-coding regions whose function is poorly understood. We integrated epigenomic and other functional annotations and derived predicted tissue-specific genetically regulated gene expression to identify relevant candidate genes.

Our GWAS of B-SEVLT, a measure of verbal learning and memory, identified three nearby and highly linked common SNVs in the intrinsic region of the gene RBM47 at 4p14. This gene encodes RNA binding motif 47, a protein that plays an important role in the regulation of alternative splicing, mRNA stability, and RNA editing. Animal studies have shown that this RNA binding protein is critical for head formation during zebrafish embryogenesis [51]. Possible mechanisms that link RBM47 to memory in primates are unknown. Intriguingly, a rare missense variant in RBM47 has been associated with blood pressure and hypertension [52], the most notable modifiable cardiovascular risk factor for both cognitive decline and dementia [53]. The identified variants at 4p14 were functionally linked to expression of another gene in the region, UBE2K, which encodes an ubiquitin-conjugating (E2) enzyme highly expressed in the brain. UBE2K has been implicated in the mediation of amyloid-β neurotoxicity and proteasome inhibition [54]. Its role in ubiquitinated protein accumulation and aggregation has been demonstrated in the pathology of several neurological diseases, including Huntington’s disease, Alzheimer’s disease, Parkinson’s disease, and schizophrenia [55-58]. The possibility that genetic variants at 4p14 may impact cognitive function through dysregulation of UBE2K function is in line with GWAS and other studies that implicate genes of the ubiquitin proteasome system in neurodegenerative diseases [59].

In addition, predicted genetically regulated expression of the gene SNX31 in the basal ganglia is suggestively associated with B-SEVLT. SNX31 encodes sorting nexin-31 which may be involved in protein trafficking. Whole exome sequencing detected a SNX31 frameshift variant in a schizophrenia patient [50]. GWAS also identified suggestive association of SNX31 variants with levels of clusterin and β-site APP cleaving enzyme in the cerebrospinal fluid [61,62], which are, both, potential biomarkers of AD.

Two indels mapping to chromosome 3p14.1 were associated with WFT, a measure of executive and verbal functioning. One is common, located ~500 bp upstream of FRMD4B, and functionally linked to the expression of
that gene. *FRMD4B* encodes FERM domain-containing protein 4B, a scaffolding protein that regulates epithelial cell polarity. This gene is one of the prominent hub genes within the myelination network implicated in LOAD. Previous GWAS also identified suggestive associations between *FRMD4B* variants with LOAD and schizophrenia. The other indel is a rare intergenic variant located in the *HLA* region at 6p21.32, which is a well-established risk locus underlying neurodegenerative diseases through neuroinflammation and immunoregulation. Interestingly, each copy of the insertion (minor) predicts an increase in the test score of approximately 6 correct words produced, suggesting a possibly protective effect of this variant. In addition, predicted genetically regulated expression of the gene *RPS6KB2* in the frontal cortex is suggestively associated with WFT. *RPS6KB2* encodes ribosomal protein S6 kinase β-2, which phosphorylates specifically ribosomal protein S6, leading to an increase in protein synthesis and cell proliferation. *RPS6KB2* is a known gene of kinases involved in tau phosphorylation, and the common variation of this gene was associated with an increased risk and a later onset of AD. Notably, frontal cortex has been recognized as the major brain structure that carries out fluency tasks. Our findings suggest a potential effect of *RPS6KB2* on the executive and verbal functioning possibly through upregulation of a tau kinase in the frontal cortex.

A locus at 10p13 that encompasses six rare SNVs in high LD was identified for DSST, a measure of psychomotor speed and sustained attention. Each additional copy of the minor allele at each variant predicted a ~10 unit decrease in the test score. These SNVs are located in the intergenic region and are potentially functionally related to a lincRNA. Fine-mapping of this locus taking into account the epigenomic context further pointed to rs142289140 (*p = 8.31 × 10^{-9}, PPA = 0.75*), a regulatory variant located at a CTCF-binding site. Interestingly, this site displays an epigenetic signature with the potential to be activated in H1-derived neuronal progenitor cultured cells. Evidence is accumulating that CTCF-dependent gene expression regulation may play a role in brain aging. Animal studies suggested that neuronal CTCF is necessary for learning and memory. Human studies also showed that genetic variants associated with neurodegenerative diseases are also enriched in CTCF-binding sites in brain tissues. These data indicate that rare SNVs in the regulatory region at 10p13 may affect human cognition through regulation of CTCF-dependent gene expression. In addition, predicted genetically regulated expression of the gene *CSPG5* in the hypothalamus is suggestively associated with DSST. *CSPG5* encodes chondroitin sulfate proteoglycan 5, present exclusively in central nervous system tissues. This protein may function as a growth and differentiation factor involved in neuronal migration and neuritogenesis. *CSPG5* has been previously implicated in schizophrenia, and has been identified as a critical target of PHF6, the protein mutated in the intellectual disability disorder Börjeson–Forssman–Lehmann syndrome. Reduced levels of brain-specific chondroitin sulfate proteoglycans, including *CSPG5*, were also associated with a delay in neurological development and the presence of a learning disability in early postnatal rats.

Our GWAS failed to identify any genome-wide significant variants for SIS, a brief and reliable instrument that measures global mental status. The dichotomization of the original ordinal measure may have reduced power of our genetic studies. Predicted genetically regulated expression of the gene *IFT122* in the hippocampus is suggestively associated with SIS. *IFT122* encodes intraflagellar transport protein 122 required for cilia formation during neuronal patterning. A genome-wide association analysis previously reported an association of an intronic variant of *IFT122* with the area of the left isthmus cingulate on neuroimaging, which potentially mediated an association of this variant with spatial orientation ability measured by the Pennsylvania line orientation test. The association of hippocampal expression of this gene with SIS is in line with the previous implication of this gene in complex cognition.

Using the GCTA-GREML approach, we estimated the variance explained by common variants for each measure of cognitive function. Power calculation showed that we have at least 80% power to detect a heritability as low as 0.12. We estimated that common variants explain a small proportion of phenotypic variance for all cognitive tests, and this was further supported by our findings of multiple rare variants associated with different cognitive tests. We also showed that the genetic correlation between most of the pairs is moderate to strong. Of note, the observation of consistent moderate/strong genetic correlation of SIS with all other measures, albeit not the case for phenotypic correlation, suggests that SIS may still be a good global measure that covers a variety of cognitive functions in genetic studies. On the other hand, relatively low and non-significant correlation between B-SEVLT, WFT, and DSST indicates that they do not share much additive genetic variance attributable to common variants and thus partly explains why the significant findings are not shared among the multiple cognitive measures.

Several limitations of our study must also be acknowledged. Though our study was carefully designed and estimation of ancestry-specific allele frequency for the associated SNVs informed our choice of study population for replication, we were unable to replicate our genome-wide significant findings in independent samples. Possible reasons include an insufficient power of the replication samples due to limited sample size and differences in allele frequency; differences in the cognitive tests...
performed in the various replication samples, though to some extent they measure similar functional domains; the relatively young age of our discovery sample; differences in the genetic architecture at the associated loci due to complex local admixture, epistasis due to differences in genetic backgrounds, and gene-by-environment interaction that may vary among different populations. In addition, we cannot rule out that our findings may be false positives possibly due to residual or unmeasured confounding unique to this admixed and diverse population. Additional studies in other large samples of Hispanics/Latinos with comparable degree of diversity are therefore warranted for further validation of these findings and for a better understanding of the genetic architecture of this population.

To facilitate interpretation and comparison of our data with published results from a large sample of mostly European ancestry, we performed a GWAS of a measure of general cognitive function (PC1) as described by Davies et al.14 No locus reached genome-wide significance likely due to low power. Six suggestive loci showed some limited evidence of association with general cognitive function in Davies et al. Notably one of the loci (3p14.1, FRMD4B) was the same as that identified in our GWAS of WFT. Only two out of 148 previously identified loci met the criteria for replication in our study. These include a locus on chromosome 4q24, which encompasses TET2, a gene encoding a DNA demethylase with known roles in the microglial inflammatory response and neurodegenerative diseases;77,78 and a locus on chromosome 13q31.2, which encompasses LINC00433 but no protein-coding gene. Taken together, these results further illustrate the need for larger samples of diverse Hispanics/Latinos and the potentially unique genetic architecture of cognitive function in this population.

Although our sample size may have limited our independent discoveries, meta-analysis of our data with the published GWAS of general cognitive function in a European ancestry sample yielded 30 additional loci reaching genome-wide significance. Among these, 26 showed little evidence of heterogeneity among the 2 studies, suggesting the possibility of shared genetic susceptibility among Hispanics/Latinos and those of European ancestry.

In conclusion, we report the results of a large-scale GWAS of cognitive function among diverse middle-aged and older US Hispanics/Latinos. We identified genome-wide significant common and rare variants associated with multiple measures of cognitive function, indicating possible candidate genes. Replication in independent Hispanic/Latino samples with the comparable level of diversity are warranted to confirm our findings. Our study underscores the pressing need for genetic investigations in large samples of Hispanics/Latinos in order to characterize the genetic underpinnings of cognitive function, which are both unique to this population and shared with populations of other ancestries.

Acknowledgements
This work was supported by the National Institute on Aging grant R01AG048862. The Hispanic Community Health Study/Study of Latinos is a collaborative study supported by contracts from the National Heart, Lung, and Blood Institute (NHLBI) to the University of North Carolina (HHSN268201300011I / N01-HC-65233), University of Miami (HHSN268201300041I / N01-HC-65254), Albert Einstein College of Medicine (HHSN268201300021I / N01-HC-65255), University of Illinois at Chicago – HHSN268201300031I / N01-HC-65236 Northwestern Univ), and San Diego State University (HHSN268201300051I / N01-HC-65237). The following Institutes/Centers/Offices have contributed to the HCHS/SOL through a transfer of funds to the NHLBI: National Institute on Minority Health and Health Disparities, National Institute on Deafness and Other Communication Disorders, National Institute of Dental and Craniofacial Research, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Neurological Disorders and Stroke, NIH Institution-Office of Dietary Supplements. The Genetic Analysis Center at the University of Washington was supported by NHLBI and NIDCR contracts (HHSN268201300005C, AM03 and MOD03). The authors thank the staff and participants of the HCHS/SOL for their important contributions. Acknowledgements and funding for the three replication samples can be found in Supplementary Information.

Author details
1Brown Foundation Institute of Molecular Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA. 2Glenn Biggs Institute for Alzheimer’s & Neurodegenerative Diseases, The University of Texas Health Science Center at San Antonio, San Antonio, TX, USA. 3Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA. 4Institute of Gerontology and Department of Health Care Sciences, Wayne State University, Detroit, MI, USA. 5Department of Epidemiology, Human Genetics and Environmental Sciences and Human Genetics Center, The University of Texas Health Science Center at Houston School of Public Health, Houston, TX, USA. 6Survey Research Center, Institute for Social Research, University of Michigan, Ann Arbor, MI, USA. 7Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA. 8Department of Behavioral Sciences, Rush Medical College, Chicago, IL, USA. 9Laboratory of Epidemiology and Population Science, National Institute on Aging, Bethesda, MD, USA. 10Department of Biostatistics, University of Washington School of Public Health, Seattle, WA, USA. 11Department of Psychology, University of Miami, Coral Gables, FL, USA. 12Division of Clinical Research, National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA. 13Department of Psychiatry, University of California, San Francisco, San Francisco, CA, USA. 14Department of Biostatistics, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, USA. 15Department of Neurology, School of Medicine and Imaging of Dementia and Aging Laboratory, Center for Neuroscience, University of California, Davis, Sacramento, CA, USA. 16Memory Impairment and Neurodegenerative Dementia (MIND) Center and Department of Medicine, The University of Mississippi Medical Center, Jackson, MS, USA. 17Department of Neurosciences and Shiley-Marcos Alzheimer’s Disease Research Center, University of California, San Diego, La Jolla, CA, USA.

Data availability
Genotype and imputed data of the HCHS/SOL can be requested via dbGaP study accession phs000880. Phenotype data can be requested via dbGaP study accession phs000810. Summary statistics for the GWAS are available upon request to the authors.

Conflict of interest
The authors declare that they have no conflict of interest.

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
52. Surendran, P. et al. Trans-ancestry meta-analyses identify rare and common variants associated with blood pressure and hypertension. Nat. Genet. 48, 1151–1161 (2016).
53. Gasecki, D., Kwarciany, M., Nyka, W. & Narkiewicz, K. Hypertension, brain damage and cognitive decline. Curr. Hypertens. Rep. 15, 547–558 (2013).
54. Song, S. et al. E2-25K/Hip-2 regulates caspase-12 in ER stress-mediated Abeta neurotoxicity. J. Cell Biol. 182, 675–684 (2008).
55. de Pri, R., Fischer, D. F., Roos, R. A. & van Leeuwen, F. W. Ubiquitin-conjugating enzyme E2-25K increases aggregate formation and cell death in polyglutamine diseases. Mol. Cell Neurosci. 34, 10–19 (2007).
56. Filatova, E. V. et al. Expression analysis of genes of ubiquitin-proteasome system in MPP7-induced mouse models of early stages of Parkinson’s disease. DoM. Biochem. Biophys. 456, 116–118 (2014).
57. Song, S. & Jung, Y. K. Alzheimer’s disease meets the ubiquitin-proteasome system. Trends Mol. Med. 10, 565–570 (2004).
58. Meiklejohn, H. et al. Blood and brain protein levels of ubiquitin-conjugating enzyme UBE2K are elevated in individuals with schizophrenia. J. Psychiatr. Res. 113, 51–57 (2019).
59. Tramutola, A., Di Domenico, F., Barone, E., Perluigi, M. & Butterfield, D. A. It is all about (U)biqution: role of altered ubiquitin-proteasome system and UCHL1 in neurodegenerative diseases: cerebrospinal fluid BACE activity. BMC Med. Genet. 19, 75 (2018).
60. Sams, D. S. et al. Neuroanatomical expression, biogenesis, and functional expression of phosphatidylinositol 3-kinase and protein kinase C signaling pathways in neurotrophins. J. Biol. Chem. 297, 24970–24978 (2006).
61. Deming, Y. et al. A potential endophenotype for Alzheimer’s disease: cerebrospinal fluid clusterin. Neurobiol. Aging 37, 208 e201–208 e209 (2016).
62. O’Malley, H. et al. Genome-wide association study identified ATP6V1H locus influencing cerebrospinal fluid BACE activity. BMC Med. Genet. 19, 78 (2018).
63. Humphries, C. E. et al. Integrated whole transcriptome and DNA methylation analysis identifies gene networks specific to late-onset Alzheimer’s disease. J. Alzheimers Dis. 44, 977–987 (2015).
64. Cummings, A. C. et al. Genome-wide association and linkage study in the Amish detects a novel candidate late-onset Alzheimer disease gene. Ann. Hum. Genet. 76, 342–351 (2012).
65. Goes, F. S. et al. Genome-wide association study of schizophrenia in Ashkenazi Jews. Am. J. Med. Genet. 85, 649–659 (2015).
66. Aliseychik, M. P., Andreeva, T. V. & Rogaev, E. I. Immunogenetic factors of neurodegenerative diseases: the role of HLA class II. Biochemistry 83, 1104–1116 (2018).
67. Vazquez-Higuera, J. L. et al. Genetic variation in the tau kinases pathway may modify the risk and age at onset of Alzheimer’s disease. J. Alzheimer’s Dis. 27, 291–297 (2011).
68. Robinson, G., Shallice, T., Buzza, M. & Cipolotti, L. The differing roles of the frontal cortex in fluency tests. Brain 135f Pt 7, 2202–2214 (2012).
69. Zerbinio, D. R., Wilder, S. P., Johnson, N., Juentemman, T. & Flisek, P. R. The ensembl regulatory build. Genome Biol. 16, 56 (2015).
70. Sams, D. S. et al. Neuronal CTCF is necessary for basal and experience-dependent gene regulation, memory formation, and genomic structure of BDNF and Arc. Cell Rep. 17, 2418–2430 (2016).
71. Gallagher, M. D. et al. A dementia-associated risk variant near TMEM106B alters chromatin architecture and gene expression. Am. J. Hum. Genet. 101, 643–663 (2017).
72. Nakanishi, K. et al. Identification of neurate outgrowth-promoting domains of neuroglycan C, a brain-specific chondroitin sulfate proteoglycan, and involvement of phosphatidylinositol 3-kinase and protein kinase C signaling pathways in neurotrophins. J. Biol. Chem. 281, 24970–24978 (2006).
73. So, H. C. et al. Identification of neuroglycan C and interacting partners as potential susceptibility genes for schizophrenia in a Southern Chinese population. Am. J. Med. Genet. B Neuropsychiatr. Genet. 153B, 103–113 (2010).
74. Zhang, C. et al. The X-linked intellectual disability protein PHF6 associates with reduced amounts of brain proteoglycans. Exp. Neurol. 219, 81–92 (2009).
75. Cummings, A. C. et al. Genome-wide mediation analysis of psychiatric and cognitive traits through imaging phenotypes. Hum. Brain Mapp. 38, 4088–4097 (2017).
76. Camillo-Jimenez, A. et al. TET2 regulates the neuroninflammatory response in microglia. Cell Rep. 29, 697–713 e698 (2019).
77. Cochran, J. N. et al. Non-coding and loss-of-function coding variants in TET2 are associated with multiple neurodegenerative diseases. Am. J. Hum. Genet. 106, 632–645 (2020).